3Emmanuel Garcion,Laurence Sindji,Serge Nataf,Philippe Brachet,Fran?oise Darcy,Claudia N. Montero-Menei. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system[J] 2003,Acta Neuropathologica(5):438～448
2Anderson S, Brenner BM. The role of intraglomemlar pressure in the initiation and progression of renal disease. J Hypertens Suppl,1986 ,4 :S236-238.
3Lefebvre HP, Toutain PL. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther,2004,27 : 265-281.
4Marin R, Ruilope LM, Aljama P, et aL A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens, 2001,19: 1871-1876.
5Buranakarl C, Kitjtawonrat A, Pondeenana S, et al. Comparison of dipyridamole and fosinopril on renal progression in nephrectomized rats. Nephrology (Carlton), 2003, 8:80-91.
6Kincald-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin Ⅱ receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant, 2002, 17 :597-601.
7Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin Ⅱ antagonists. Kidney Int,2000, 57 : 1803-1817.
8Donner H, Rau H, Walfish PG, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 143-146.
9Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest, 2002,109 : 295-299.
10Ligers A, Teleshova N, Masterman T, et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun ,2001,2 : 145-152.
